

Amendments to the claims:

This listing of the claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1. (Canceled)
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Currently Amended) The medicament according to claim 15, ~~which is formulated for~~ wherein said pharmaceutical formulation comprises a parenteral administration solution.
11. (Canceled)
12. (Canceled)
13. (Canceled)
14. (Canceled)
15. (Currently Amended) A medicament for allergen-specific immunotherapy capable of ~~generating an immunoprotective response~~ inducing strong antibody responses with less granulomatous tissue reactions, said medicament containing a therapeutically effective amount of microparticles in a pharmaceutical formulation, said microparticles consisting essentially of comprising:
 - (a) a bead consisting of ~~a~~ three-dimensionally cross-linked carbohydrate selected from the group consisting of polyarylamide, vinyl polymer,

~~dextran, agarose, and mixtures thereof; and~~

- (b) a purified recombinant polypeptide allergen derived from plant pollen ~~covalently~~ bound to said bead by means of a covalent bond between said cross-linked agarose and a reactive group of said allergen.

16. (Canceled)
17. (Previously Presented) The medicament according to claim 15, wherein the carbohydrate bead comprises cyanogen bromide-activated spherical agarose.
18. (Previously Presented) The medicament according to claim 15, wherein the allergen is derived from grass pollen.
19. (Previously Presented) The medicament according to claim 18, wherein the grass pollen allergen is derived from timothy grass pollen.
20. (Previously Presented) The medicament according to claim 19, wherein the timothy grass pollen allergen is the Phl p 5b allergen of SEQ ID NO: 1.
21. (Previously Presented) The medicament according to claim 21, wherein the particle size ranges from 0.1 μm to 10 μm .
22. (Previously Presented) The medicament according to claim 21, wherein the particle size ranges from 0.5 μm to 5 μm .
23. (Currently Amended) The medicament according to claim 15, wherein the three-dimensionally cross-linked agarose carbohydrate bead comprises—consists essentially of cyanogen bromide-activated spherical agarose and the polypeptide allergen comprises—consists essentially of the timothy grass pollen allergen Phl p 5b of SEQ ID NO:1.
24. (New) The medicament according to claim 15, wherein the pharmaceutical formulation is selected from the group consisting of an injectable solution, rectal foam, nasal spray, ointment and plaster.